Baker Bros. Advisors LP Immuno Gen, Inc. Transaction History

Baker Bros. Advisors LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $5.7 Million - $30.5 Million	1,520,097 New	1,520,097 $28.7 Million
Q1 2018 May 15, 2018	SELL	$6.7 - $12.95 $17.2 Million - $33.2 Million	-2,563,489 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$5.07 - $7.92 $633,750 - $990,000	-125,000 Reduced 4.65%	2,563,489 $16.4 Million
Q3 2017 Nov 14, 2017	BUY	$5.4 - $8.47 $14.5 Million - $22.8 Million	2,688,489	2,688,489 $20.6 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.